NanoViricides Files Application For Orphan Drug Designation For NV-387 To Treat Measles

NanoViricides, Inc., a publicly traded company (NYSE American:NNVC) (the "Company"), and a clinical stage, leading global pioneer in the development of broad-spectrum antivirals based on host-mimetic nanomedicine technology that viruses cannot escape, announced today that it has filed an application for "Orphan Drug Designation" (ODD) for NV-387 as a Treatment for Measles with the US FDA Office of Orphan Products Development (OOPD).

If approved, orphan drug designation will qualify NanoViricides for incentives including:

Tax credits for qualified clinical trials;

Exemption from certain user fees;

Potential seven years of market exclusivity after approval